Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

The treatment of obesity can no longer be reduced to a simplistic view of weight loss.
Metabolic adaptation leads to systematic weight regain following weight-loss efforts, and …

Overweight and obesity are one of the most relevant health factors; according to the WHO,
39% of people globally are overweight and 13% obese. 1 Body weight loss of 3%–5% has …

The OASIS 1 trial by Filip K Knop and colleagues1 demonstrates the greatest magnitude of
weight loss to date among oral anti-obesity medications. 2− 4 In this randomised, double …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Global average data suggest that the prevalence of male obesity is increasing and that its
prevalence in some regions of Western Europe, Japan, China, Korea and USA is higher …

The landscape of pharmacological interventions in combating obesity has long struggled
with the formidable challenge of balancing efficacy and safety, with weightloss drugs often …

Over the long, checkered history of weight-loss drugs, a safe and highly effective medication
has been the elusive holy grail. The handful of drugs currently approved for long-term …

Background Semaglutide 2· 4 mg once weekly has been investigated for weight
management in global populations. Differences exist between Asian and non-Asian …

Background Management guidelines for obesity suggest maintaining a minimum of 5% body
weight reduction to help prevent or lower the risk of developing conditions such as …